PureTech Health plc

PRTC

GB00BY2Z0H74

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 11:35:20 2024-04-26 am EDT			5-day change	1st Jan Change
218 ^GBX	+2.59%		+5.57%	+12.26%

Apr. 25	Transcript : PureTech Health plc, 2023 Earnings Call, Apr 25, 2024
Apr. 25	PureTech touts "momentum" as grants shrivel but annual loss narrows	AN

PureTech Health plc(LSE:PRTC) added to FTSE 250 Index

September 19, 2022 at 12:00 am EDT

Latest news about PureTech Health plc

Transcript : PureTech Health plc, 2023 Earnings Call, Apr 25, 2024	Apr. 25
PureTech touts "momentum" as grants shrivel but annual loss narrows	Apr. 25	AN
Miner Anglo American reviews takeover bid from rival BHP	Apr. 25	AN
Miner Anglo American eyes rival BHP takeover	Apr. 25	AN
Correction: Earnings Flash (PRTC.L) PURETECH HEALTH Posts FY23 Loss $-0.24	Apr. 25	MT
Earnings Flash (PRTC.L) PURETECH HEALTH Reports FY23 Revenue $3.3M	Apr. 25	MT
Earnings Flash (PRTC.L) PURETECH HEALTH Posts FY24 Loss $-0.24	Apr. 25	MT
PureTech Health plc Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 25	CI
EARNINGS AND TRADING: J Smart boosts revenue, Tertiary starts drilling	Apr. 16	AN
PureTech Health plc Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis	Apr. 16	CI
US FDA hands fast track to PureTech head and neck cancer treatment	Apr. 11	AN
PureTech Health plc Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers	Apr. 11	CI
PureTech Health CEO Zohar moves to head-up portfolio firm Seaport	Apr. 09	AN
PureTech Health Names Bharatt Chowrira Chief Executive; Receives $100 Million in Funding for Seaport Therapeutics Startup	Apr. 09	MT
PureTech Health's Seaport Therapeutics Raises $100 Million at Launch	Apr. 09	MT
PureTech Health CEO Steps Down; Successor Named	Apr. 09	MT
PureTech Health plc Announces Chief Executive Officer Changes	Apr. 09	CI
PureTech Health plc Announces Management Changes	Apr. 09	CI
Seaport Therapeutics announced that it has received $100 million in funding from Arch Venture Partners, L.P., Sofinnova Investment, Inc., Third Rock Ventures, LLC, PureTech Health plc	Apr. 08	CI
ADRs End Flat, Ehang Holdings Ltd. Climbs 15.6%	Mar. 19	DJ
European large-caps rise on eve of Fed decision	Mar. 19	AN
Tranche Update on PureTech Health plc's Equity Buyback Plan announced on May 5, 2022.	Mar. 19	CI
PureTech shares jump on USD100 million tender offer proposal	Mar. 19	AN
PureTech Health to Return $100 Million to Shareholders via Tender Offer	Mar. 19	MT
PureTech Health Proposes $100 Million Capital Return	Mar. 19	MT

PureTech Health plc is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company's R&D engine has developed 27 therapeutics and therapeutic candidates, including two (Plenity and EndeavorRx) that have received both United States (US) Food and Drug Administration (FDA) clearance and European marketing authorization. The Company's pipeline includes LYT-100, LYT-200, LYT-300, LYT-310 and LYT-503/IMB-150. LYT-100 (deupirfenidone) is being advanced for the potential treatment of conditions involving inflammation and fibrosis. It is developing LYT-200 for the treatment of metastatic/locally advanced solid tumors that have poor survival rates, including urothelial and head and neck cancers. LYT-300 is an oral prodrug of allopregnanolone, which is being advanced for the potential treatment of anxiety disorders and postpartum depression.

Sector

Biotechnology & Medical Research

Calendar

2024-08-26 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for PureTech Health plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.655 USD

Average target price

6.205 USD

Spread / Average Target

+133.72%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PURETECH HEALTH PLC	+12.26%	717M
IQVIA HOLDINGS INC.	+1.51%	42.59B
MODERNA, INC.	+8.57%	40.65B
LONZA GROUP AG	+49.22%	40.57B
CELLTRION, INC.	-12.36%	26.77B
ICON PUBLIC LIMITED COMPANY	+8.92%	24.81B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.17B
MEDPACE HOLDINGS, INC.	+29.17%	12.05B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.7B
UNITED THERAPEUTICS CORPORATION	+6.35%	11.1B

Other Biotechnology & Medical Research